|| Protez Pharmaceuticals ||

Investors - Meeting The Urgent Need For New Antibiotics

Protez Pharmaceuticals has successfully raised approximately $26 MM in capital from the following sources to fund clinical development of PZ-601 and to advance discovery programs:

Source Funds
Grants $3,300,000
Private Equity $23,000,000

Current Investors:

Birchmere

http://www.birchmerevc.com/

Bioadvance Ventures

http://www.bioadvanceventures.com/

Quaker Bioventures

http://www.quakerbio.com/

S.R. One

http://www.srone.com/

L-Capital Partners

http://www.lcapital.us/

BTGplc

http://www.btgplc.com/

BioAdvance

http://www.bioadvance.com/

Ben Franklin Technology Partners

http://www.benfranklin.org/

Easton Capital

http://www.eastoncapital.com/

Robin Hood Ventures

www.robinhoodventures.com/